Cargando…

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort

OBJECTIVE: Few data exist about the effect of dolutegravir (DTG) on bone mineral density (BMD) in real life. The aim of this study was to determine rates of change in BMD over time in people living with HIV (PLWH) treated with DTG. DESIGN: The SCOLTA project is a multicenter observational study enro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bonfanti, Paolo, De Vito, Andrea, Ricci, Elena, Menzaghi, Barbara, Orofino, Giancarlo, Squillace, Nicola, Molteni, Chiara, De Socio, Giuseppe Vittorio, Salomoni, Elena, Celesia, Benedetto Maurizio, Dentone, Chiara, Colombo, Valeria, Madeddu, Giordano
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368553/ https://www.ncbi.nlm.nih.gov/pubmed/32765005 http://dx.doi.org/10.2147/IDR.S260449

Ejemplares similares

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
por: Bagella, Paola, et al.
Publicado: (2019)

Trajectories of CD4(+)/CD8(+) T-Cells Ratio 96 Weeks after Switching to Dolutegravir-Based Two-Drug Regimens: Results from a Multicenter Prospective Cohort Study
por: Taramasso, Lucia, et al.
Publicado: (2022)

Factors Associated With Weight Gain in People Treated With Dolutegravir
por: Taramasso, Lucia, et al.
Publicado: (2020)

Lipids and transaminase elevations in ARV-experienced PLWH switching to a doravirine-based regimen from rilpivirine or other regimens
por: Maggi, Paolo, et al.
Publicado: (2023)

Reversibility of Central Nervous System Adverse Events in Course of Art
por: Taramasso, Lucia, et al.
Publicado: (2022)

Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study
por: De Vito, Andrea, et al.
Publicado: (2023)

Durability, safety, and efficacy of rilpivirine in clinical practice: results from the SCOLTA Project
por: Bagella, Paola, et al.
Publicado: (2018)

Weight Gain: A Possible Side Effect of All Antiretrovirals
por: Taramasso, Lucia, et al.
Publicado: (2017)

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2019)

Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?
por: Maggi, Paolo, et al.
Publicado: (2022)

Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting
por: Maggi, Paolo, et al.
Publicado: (2023)

Improvement of lipid profile after switching from efavirenz or ritonavir-boosted protease inhibitors to rilpivirine or once-daily integrase inhibitors: results from a large observational cohort study (SCOLTA)
por: Taramasso, Lucia, et al.
Publicado: (2018)

Smoking habits in HIV-infected people compared with the general population in Italy: a cross-sectional study
por: De Socio, Giuseppe Vittorio, et al.
Publicado: (2020)

The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile
por: Squillace, Nicola, et al.
Publicado: (2020)

Clusterization of co-morbidities and multi-morbidities among persons living with HIV: a cross-sectional study
por: Maggi, Paolo, et al.
Publicado: (2019)

Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project
por: Squillace, Nicola, et al.
Publicado: (2017)

Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV
por: Guaraldi, Giovanni, et al.
Publicado: (2021)

Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir
por: Squillace, Nicola, et al.
Publicado: (2023)

Switch to Dolutegravir plus Rilpivirine Dual Therapy in cART-Experienced Subjects: An Observational Cohort
por: Capetti, Amedeo F., et al.
Publicado: (2016)

Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort
por: Focà, Emanuele, et al.
Publicado: (2021)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
por: Capetti, Amedeo F., et al.
Publicado: (2017)

96 Week Follow-Up of HIV-Infected Patients in Rescue with Raltegravir Plus Optimized Backbone Regimens: A Multicentre Italian Experience
por: Capetti, Amedeo, et al.
Publicado: (2012)

Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort
por: Nicolini, Laura Ambra, et al.
Publicado: (2023)

Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE)
por: Ciccullo, Arturo, et al.
Publicado: (2019)

Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian “GEPPO” Cohort
por: Focà, Emanuele, et al.
Publicado: (2019)

Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
por: Antinori, Andrea, et al.
Publicado: (2020)

Correction to: Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression
por: Antinori, Andrea, et al.
Publicado: (2020)

HIV and SARS-CoV-2 Co-Infection: What are the Risks?
por: Squillace, Nicola, et al.
Publicado: (2021)

Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: results from a multicenter study
por: Madeddu, G, et al.
Publicado: (2010)

Is Dolutegravir Plus Atazanavir Overburdened With Concentration-Related Neurological Events Compared With Other Dual Regimens?
por: Capetti, Amedeo F, et al.
Publicado: (2019)

Real-World Experience with Dolutegravir-Based Two-Drug Regimens
por: Ward, Douglas, et al.
Publicado: (2020)

Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The “STORE” Study
por: Gori, Andrea, et al.
Publicado: (2020)

Dolutegravir: Virologic response and tolerability of initial antiretroviral regimens for adults living with HIV
por: Correa, Analú, et al.
Publicado: (2020)

1009. Dolutegravir and Doravirine in Combination: When Standard Antiretroviral Regimens are Unacceptable
por: Denyer, Rachel, et al.
Publicado: (2020)

Neurocognitive improvement in HIV-positive patients treated with dolutegravir-based regimens
por: Rodrigues, Janine, et al.
Publicado: (2023)

Factors associated with HIV-1 resistance to integrase strand transfer inhibitors in Spain: Implications for dolutegravir-containing regimens
por: Gil, Horacio, et al.
Publicado: (2022)

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV
por: Martínez-Sanz, Javier, et al.
Publicado: (2022)

First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens
por: Fokam, Joseph, et al.
Publicado: (2020)

2485. Real-world Experience with Dolutegravir Plus Rilpivirine Two-Drug Regimen
por: Ward, Douglas, et al.
Publicado: (2019)

The DoDo experience: an alternative antiretroviral 2-drug regimen of doravirine and dolutegravir
por: Sammet, Stefanie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dtjvq4ps3hdbfqr25uca1hrkdq